Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.

Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG.

Eur Urol. 2017 Nov;72(5):665-674. doi: 10.1016/j.eururo.2017.04.034. Epub 2017 May 13.

PMID:
28511883
2.

Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.

Hoogland AM, Böttcher R, Verhoef E, Jenster G, van Leenders GJ.

Oncotarget. 2016 Jun 21;7(25):37846-37856. doi: 10.18632/oncotarget.9344.

3.

MET expression during prostate cancer progression.

Verhoef EI, Kolijn K, De Herdt MJ, van der Steen B, Hoogland AM, Sleddens HF, Looijenga LH, van Leenders GJ.

Oncotarget. 2016 May 24;7(21):31029-36. doi: 10.18632/oncotarget.8829.

4.

The role of HOXC6 in prostate cancer development.

Hamid AR, Hoogland AM, Smit F, Jannink S, van Rijt-van de Westerlo C, Jansen CF, van Leenders GJ, Verhaegh GW, Schalken JA.

Prostate. 2015 Dec;75(16):1868-76. doi: 10.1002/pros.23065. Epub 2015 Aug 27.

PMID:
26310814
5.

Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.

Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Souza Queiroz KC, Peppelenbosch MP, Stubbs AP, Pelizzaro-Rocha K, van Leenders GJLH, Jenster G, Aoyama H, Ferreira CV, Fuhler GM.

Eur Urol. 2016 Apr;69(4):710-719. doi: 10.1016/j.eururo.2015.06.040. Epub 2015 Jul 7.

PMID:
26159288
6.

Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer.

Böttcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G.

Oncotarget. 2015 Feb 28;6(6):4036-50.

7.

Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2015 Feb 11;16(2):3856-69. doi: 10.3390/ijms16023856.

8.

SYK is a candidate kinase target for the treatment of advanced prostate cancer.

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH.

Cancer Res. 2015 Jan 1;75(1):230-40. doi: 10.1158/0008-5472.CAN-14-0629. Epub 2014 Nov 11.

9.

Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review.

Hoogland AM, Kweldam CF, van Leenders GJ.

Biomed Res Int. 2014;2014:341324. doi: 10.1155/2014/341324. Epub 2014 Aug 27. Review.

10.

Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.

Duijvesz D, Burnum-Johnson KE, Gritsenko MA, Hoogland AM, Vredenbregt-van den Berg MS, Willemsen R, Luider T, Paša-Tolić L, Jenster G.

PLoS One. 2013 Dec 31;8(12):e82589. doi: 10.1371/journal.pone.0082589. eCollection 2013.

11.

Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.

Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, Jenster G, van Leenders GJ.

Prostate. 2014 May;74(5):488-96. doi: 10.1002/pros.22768. Epub 2013 Dec 27.

PMID:
24375374
12.

Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2013 Jun 3;14(6):11816-29. doi: 10.3390/ijms140611816.

13.

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ.

Mod Pathol. 2012 Mar;25(3):471-9. doi: 10.1038/modpathol.2011.176. Epub 2011 Nov 11.

14.

Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours.

Rijlaarsdam MA, van Herk HA, Gillis AJ, Stoop H, Jenster G, Martens J, van Leenders GJ, Dinjens W, Hoogland AM, Timmermans M, Looijenga LH.

Br J Cancer. 2011 Sep 6;105(6):854-63. doi: 10.1038/bjc.2011.270. Epub 2011 Aug 16. Erratum in: Br J Cancer. 2012 Feb 14;106(4):791.

15.

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J.

Mod Pathol. 2011 Aug;24(8):1128-38. doi: 10.1038/modpathol.2011.65. Epub 2011 Apr 15.

16.

Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.

Hoogland AM, Dahlman A, Vissers KJ, Wolters T, Schröder FH, Roobol MJ, Bjartell AS, van Leenders GJ.

BJU Int. 2011 Oct;108(8):1356-62. doi: 10.1111/j.1464-410X.2010.10059.x. Epub 2011 Mar 16.

Supplemental Content

Loading ...
Support Center